Thomas Han

TL;DR: The crystal structure of one such nAb bound to H5 shows that it blocks infection by inserting its heavy chain into a conserved pocket in the stem region, thus preventing membrane fusion, and suggests that nAb-based immunotherapy is a promising strategy for broad-spectrum protection against seasonal and pandemic influenza viruses.

TL;DR: Current knowledge of the structure‐based mechanisms contributing to the neutralization and neutralization escape of influenza viruses are reviewed and the potential for this structure-based approach to overcome the obstacles in developing the highly desired “universal” influenza vaccine is explored.

TL;DR: The data demonstrate that the in vivo anti-tumor activity of h1567 minibody is mediated, at least in part, through CD16A+ immune effector cell ADCC mechanisms, and further demonstrate the utility of the AAV-minibody gene transfer system in the rapid evaluation of candidate anti-Tumor mAbs and the potency of h 1567 as a potential novel therapy for CTCL.

TL;DR: A robust yeast display system for fine epitope mapping of viral surface hemagglutinin (HA)-specific antibodies is demonstrated, giving insight into the mechanism underlying its potent inhibition of virus binding.

TL;DR: W whole-genome population sequencing enables the identification of viral resistance mutations responding to antibody-induced selective pressure and shows that NA mutations mediate the escape of neutralization by antibodies against HA, highlighting the importance of a balance between HA and NA for optimal virus function.